Investigational drug · Phase 2
MK-1439A
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Human Immunodeficiency Virus (HIV) Infection.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
7
Any phase or sponsor naming "MK-1439A"
First trial start
2021
Feb 3, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MK-1439A", any sponsor or status.
Conditions studied
As listed on its trial records.
- Human Immunodeficiency Virus (HIV) Infection
Approved drugs for the same conditions: Infectious disease and vaccines · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "MK-1439A" as an intervention, largest first.
- Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02403674 · 734 participants · Start Jun 5, 2015 · Primary completion Mar 20, 2017
Drug: Doravirine, Tenofovir, Lamivudine; ATRIPLA™ and 1 more · For: Human Immunodeficiency Virus (HIV)
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02397096 · 673 participants · Start Jun 9, 2015 · Primary completion Feb 22, 2018
Drug: Doravirine, Tenofovir, Lamivudine; Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor and 3 more · For: HIV-1 Infection
- Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03272347 · 123 participants · Start Nov 27, 2017 · Primary completion Mar 8, 2021
Drug: Islatravir; Placebo to Islatravir and 7 more · For: HIV-1 Infection
Sites: Phoenix, Arizona; Sacramento, California; Washington D.C., District of Columbia · 26 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02652260 · 86 participants · Start Mar 4, 2016 · Primary completion Aug 14, 2018
Drug: Doravirine, Tenofovir, Lamivudine - Blinded; Doravirine, Tenofovir, Lamivudine - Open-Label and 3 more · For: HIV-1; Central Nervous System
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04375800 · 84 participants (planned) · Start Feb 3, 2021 · Primary completion Nov 12, 2028
Drug: Doravirine; 2 NRTIs and 1 more · For: Human Immunodeficiency Virus (HIV) Infection
Sites: Aurora, Colorado; Atlanta, Georgia; Rionegro, Colombia · 26 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT03332095 · 55 participants · Start Jul 2, 2018 · Primary completion Aug 19, 2020
Drug: Doravirine (DOR); Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) and 1 more · For: HIV Infections
Sites: Aurora, Colorado; Boston, Massachusetts; Memphis, Tennessee · 8 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02629822 · 10 participants · Start Jan 14, 2016 · Primary completion Nov 28, 2018
Drug: Doravirine/lamivudine/tenofovir disoproxil fumarate · For: HIV-1 Infection
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy, Safety, and Tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Results Through Week 96 from IMPAACT 2014.
Rungmaitree S, Aurpibul L, Best BM, et al. · J Pediatric Infect Dis Soc 2023
Also in development for Human Immunodeficiency Virus (HIV) Infection
- 2 NRTIsPhase 32 trials
Merck & Co. · Human Immunodeficiency Virus (HIV) Infection, Infection, Human Immunodeficiency Virus, HIV Infections
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.